5 stories mentioning CLYMUpdated 14d ago
Every FINWIRES story that references CLYM, newest first.
Climb Bio (CLYM) has an average rating of buy and mean price target of $19.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Climb Bio (CLYM) has an average rating of buy and mean price target of $18.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $11.98, Change: $+0.53, Percent Change: +4.63%
Climb Bio (CLYM) has an average rating of buy and mean price target of $16.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Climb Bio (CLYM) is drawing increased analyst optimism following updated expectations for its immunology pipeline, particularly its investigational therapies for IgA nephropathy, Oppenheimer said in a Tuesday note.Oppenheimer highlighted growing confidence in Climb Bio's anti-APRIL programs, including CLYM116, citing potential best-in-class efficacy, stronger-than-expected proteinuria reduction, longer dosing intervals, and a favorable safety profile as key differentiators.According to the report, upcoming clinical readouts for subcutaneous budoprutug and CLYM116 could serve as key catalysts, potentially validating Climb Bio's IgAN approach, with strong pricing dynamics supporting commercial upside if results are positive.Oppenheimer maintained its outperform rating on the stock and raised its price target to $18 from $10.Shares of Climb Bio were up more than 6% in Tuesday trading.Price: $9.49, Change: $+0.52, Percent Change: +5.80%
Climb Bio (CLYM) has an average rating of buy and mean price target of $15.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
